Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OVV-01 + IBR900
- Development stage
- Unknown
- Lead developer
- Joint Biosciences
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intratumoral, Intravenous
01
Overview
OVV-01 + IBR900 is a combination immunotherapy being evaluated for the treatment of advanced solid tumors and relapsed/refractory lymphomas. OVV-01 is an oncolytic virus based on a genetically engineered vesicular stomatitis virus (VSV) platform, designed to selectively replicate within tumor cells and express the cancer-testis antigen NY-ESO-1. This expression is intended to stimulate a targeted immune response against NY-ESO-1-positive cells. IBR900 is a cell therapy consisting of trained immunity natural killer (tiNK) cells, which are NK cells that have been "trained" to exhibit enhanced cytotoxic activity and longevity compared to conventional NK cells. The combination therapy aims to achieve synergistic anti-tumor effects by combining direct viral oncolysis, antigen-driven immune activation, and potent NK cell-mediated killing. The program is being developed by Shanghai Joint Biosciences and Imbioray, with clinical evaluation ongoing in investigator-initiated trials.
- Other names
- OVV-01 plus IBR900OVV01 plus IBR900OVV 01 plus IBR900
Beyond the preview
Go deeper on OVV-01 + IBR900.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OVV-01 + IBR900.